Foghorn Therapeutics Inc., a Cambridge, Mass.-based startup devoted to developing new cancer drugs that exploit the chromatin regulatory system to direct gene expression, has launched with an initial capital commitment of $50 million from Flagship Pioneering, the 17-year-old venture firm previously known as Flagship Ventures.